Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“
Medexus”) (TSXV: MDP) (OTCQX: MEDXF)
(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class .
Medexus Pharmaceuticals IncFebruary 2, 2021 GMT
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“Medexus Pharma” and together with Medexus, the “Company”) entered into a Commercialization and Supply Agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. (“medac”), pursuant to which medac has granted Medexus Pharma an excl